Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited

CLVLF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$249.91M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Clinuvel Pharmaceuticals LimitedClinuvel Pharmaceuticals Limited10.90.67%29%1.7-
$9.53

Current Fair Value

92.4% upside

Undervalued by 92.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$249.91 Million
Enterprise Value$214.15 Million
Annual dividend$0.04
Dividend yield0.67%
Earnings per Share$0.68
Beta0.57
Outstanding Shares49,755,000

Return

Return on Equity28.59%ROE
Return on Assets26.40%
Return on Invested Capital36.30%

Valuation & Multiples

P/E Ratio10.91P/E Ratio
PEG-40.16PEG
Price to Sales1.65Price to Sales
Price to Book Ratio1.24Price to Book Ratio
Enterprise Value to Revenue1.15
Enterprise Value to EBIT2.35
Enterprise Value to Net Income3
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 26, 2026
EPS
$0.33
Est. $0.35
Revenue
$39.50 M
Est. $41.51 M

Next Earnings Call

Expected Date
February 23, 2027
EPS Estimate
$0.17
Consensus analyst estimate
Revenue Estimate
$24.40 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Clinuvel Pharmaceuticals Limited

109 employees
CEO: Philippe Jacques Wolgen

Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from g...